Santurus: Fundamentals Unchanged!

Recently, an article from Seeking Alpha has got me scratching my head! The title: “Santarus: Business Fundamentals Improving”, which was written by an analyst from Zack’s. The article highlighted recent additions to Santarus’s business plan through the in-licensing of: Glumetza, Budenoside, and Rifamycin. Furthermore, the article suggested that these additions are net positive since little-to-no […]

DepoMed: Protected by Cash and Headed Higher

Recently, my partner has made some great stock picks for his portfolio. The markets now are truly once in a lifetime and these sort of gyrations can present huge opportunities to us small time investors. His portfolio is up 75% month-over-month. I got to give him props. But let me make a case for Depomed (NASDAQ:DEPO). […]